The management of genital candidosis with an oral antimycotic agent, ketoconazole.
Fifty-three women with clinical evidence of vaginal candidosis confirmed by culture were entered into an open study. Patients received 400 mg ketoconazole once daily for 5 days. At 2 weeks post-treatment, 49 (92.5%) showed clinical and microbiological remission. The remaining 4 patients received 400 mg ketoconazole once daily for a further 21 days, along with a 400 mg 5-day course for their sexual partners. On completion of this second course of treatment, 3 of these patients were cured. Apart from some mild nausea, no side-effects were reported or observed.
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000009:adverse effects; D002181:Candidiasis, Vulvovaginal / Q000188:drug therapy* / Q000209:etiology; D003276:Contraceptives, Oral / Q000009:adverse effects; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007434:Intrauterine Devices / Q000009:adverse effects; D007654:Ketoconazole / Q000627:therapeutic use*; D008875:Middle Aged; D012008:Recurrence
D000900:Anti-Bacterial Agents; D003276:Contraceptives, Oral; D007654:Ketoconazole